Recall for U.S. Only Country Sites Search Policies and Documents SAFE HARBOUR The documents contain forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995 . We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual result to differ materially. Such factors include, but are not limited to, changes in general economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future. This communication is not an offer to sell or the solicitation of an offer to buy securities Click below if you accept these conditions Accept OUR STORY About Us Who We Are Our Heritage Leadership Featured Stories our employees respond covid19 OUR PRODUCTS Business Focus Quality Therapeutic Focus OUR SCIENCE Research Philosophy Development Streams Capabilities OUR PEOPLE & CITIZENSHIP Life at Dr.Reddy's Humans of Dr. Reddy’s Patients Healthcare Professionals Community Planet Affiliates Sustainability Terms Of Use Privacy Policy Accessibility Cookie Policy © 2021 Dr. Reddy’s Laboratories Ltd. All rights reserved. Cookie This website uses cookies to help us give you the best experience when you visit. By using this website you consent to our use of cookies. For more information please review our cookie policy. Cookie Policy. ACCEPT

Recall for U.S. Only Country Sites Search 1984 1991 1995 2001 2007 2010 2014 2020 1984 The birth of a dream Scientist and entrepreneur Dr. K Anji Reddy established Dr. Reddy’s Laboratories with the vision to make medicines accessible to everyone. Beginning with the manufacture of active ingredients (APIs) for Ibuprofen and then Methyldopa, the anti-hypertensive drug previously unavailable in India, we later branched into formulations. In 1988, we became the largest exporter of Ibuprofen API in India with sales to the US, Spain, Italy and Japan. We also began to export active ingredients for Norfloxacin and Ciprofloxacin to Europe and the Far East in 1990. This was a first for an Indian pharmaceutical company. OUR STORY About Us Who We Are Our Heritage Leadership Featured Stories our employees respond covid19 OUR PRODUCTS Business Focus Quality Therapeutic Focus OUR SCIENCE Research Philosophy Development Streams Capabilities OUR PEOPLE & CITIZENSHIP Life at Dr.Reddy's Humans of Dr. Reddy’s Patients Healthcare Professionals Community Planet Affiliates Sustainability Terms Of Use Privacy Policy Accessibility Cookie Policy © 2021 Dr. Reddy’s Laboratories Ltd. All rights reserved. Cookie This website uses cookies to help us give you the best experience when you visit. By using this website you consent to our use of cookies. For more information please review our cookie policy. Cookie Policy. ACCEPT